研究者業績

小野 啓

オノ ヒラク  (Hiraku Ono)

基本情報

所属
千葉大学 予防医学センター 教授
学位
医学博士(2001年3月 東京大学)

J-GLOBAL ID
200901067300291495
researchmap会員ID
5000005052

学歴

 2

委員歴

 1

論文

 117
  • Hideyuki Sakoda, Takehide Ogihara, Motonobu Anai, Midori Fujishiro, Hiraku Ono, Yukiko Onishi, Hideki Katagiri, Miho Abe, Yasushi Fukushima, Nobuhiro Shojima, Kouichi Inukai, Masatoshi Kikuchi, Yoshitomo Oka, Tomoichiro Asano
    American Journal of Physiology-Endocrinology and Metabolism 282(6) E1239-E1244 2002年6月1日  査読有り
    5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) reportedly activates AMP-activated protein kinase (AMPK) and stimulates glucose uptake by skeletal muscle cells. In this study, we investigated the role of AMPK in AICAR-induced glucose uptake by 3T3-L1 adipocytes and rat soleus muscle cells by overexpressing wild-type and dominant negative forms of the AMPKα2 subunit by use of adenovirus-mediated gene transfer. Overexpression of the dominant negative mutant had no effect on AICAR-induced glucose transport in adipocytes, although AMPK activation was almost completely abolished. This suggests that AICAR-induced glucose uptake by 3T3-L1 adipocytes is independent of AMPK activation. By contrast, overexpression of the dominant negative AMPKα2 mutant in muscle markedly suppressed both AICAR-induced glucose uptake and AMPK activation, although insulin-induced uptake was unaffected. Overexpression of the wild-type AMPKα2 subunit significantly increased AMPK activity in muscle but did not enhance glucose uptake. Thus, although AMPK activation may not, by itself, be sufficient to increase glucose transport, it appears essential for AICAR-induced glucose uptake in muscle.
  • N. Shojima, H. Sakoda, T. Ogihara, M. Fujishiro, H. Katagiri, M. Anai, Y. Onishi, H. Ono, K. Inukai, M. Abe, Y. Fukushima, M. Kikuchi, Y. Oka, T. Asano
    Diabetes 51(6) 1737-1744 2002年6月1日  査読有り
  • Yamada Tetsuya, Katagiri Hideki, Asano Tomoichiro, Tsuru Masatoshi, Inukai Kouichi, Ono Hiraku, Kodama Tatsuhiko, Kikuchi Masatoshi, Oka Yoshitomo
    Am J Physiol Endocrinol Metab 282(6) E1385-94 2002年6月  査読有り
  • 小野 啓, 浅野 知一郎, 山田 哲也, 片桐 秀樹, 犬飼 浩一, 穴井 元暢, 大西 由希子, 藤城 緑, 宋 海燕, 菊地 方利
    糖尿病 45(Suppl.2) S168-S168 2002年4月  
  • Yukiko Onishi-Haraikawa, Makoto Funaki, Noriko Gotoh, Masabumi Shibuya, Kouichi Inukai, Hideki Katagiri, Yasushi Fukushima, Motonobu Anai, Takehide Ogihara, Hideyuki Sakoda, Hiraku Ono, Masatoshi Kikuchi, Yoshitomo Oka, Tomoichiro Asano
    Biochemical and Biophysical Research Communications 288(2) 476-482 2001年10月  
  • H Ono, H Katagiri, M Funaki, M Anai, K Inukai, Y Fukushima, H Sakoda, T Ogihara, Y Onishi, M Fujishiro, M Kikuchi, Y Oka, T Asano
    MOLECULAR ENDOCRINOLOGY 15(8) 1411-1422 2001年8月  査読有り
    To investigate the roles of PTEN (phosphatase and tensin homolog deleted on chromosome 10) in the regulation of 3-position phosphorylated phosphoinositide metabolism as well as insulin-induced Akt phosphorylation and glucose metabolism, wildtype PTEN and its phosphatase-dead mutant (C124S) with or without an N-terminal myristoylation tag were overexpressed in Sf-9 cells and 3T3-L1 adipocytes using baculovirus and adenovirus systems, respectively. When expressed in Sf-9 cells together with the p110 alpha catalytic subunit of phosphoinositide 3-kinase, myristoylated PTEN markedly reduced the accumulations of both phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate induced by p110 alpha. In contrast, overexpression of the C124S mutants apparently increased these accumulations. In 3T3-L1 adipocytes, insulin-induced accumulations of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate were markedly suppressed by overexpression of wild-type PTEN with the N-terminal myristoylation tag, but not by that without the tag. On the contrary, the C124S mutants of PTEN enhanced insulin-induced accumulations of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate. Interestingly, the phosphorylation level of Akt at Thr308 (Akt2 at Thr309), but not at Ser473 (Akt2 at Ser474), was revealed to correlate well with the accumulation of phosphatidylinositol 3,4,5-trisphosphate modified by overexpression of these PTEN proteins. Finally, insulin-induced increases in glucose transport activity were significantly inhibited by the overexpression of myristoylated wild-type PTEN, but were not enhanced by expression of the C124S mutant of PTEN. Therefore, in conclusion, 1) PTEN dephosphorylates both phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate in vivo, and the C124S mutants interrupt endogenous PTEN activity in a dominant-negative manner. 2) The membrane targeting process of PTEN may be important for exerting its function. 3) Phosphorylations of Thr309 and Ser474 of Akt2 are regulated differently, and the former is regulated very sensitively by the function of PTEN. 4) The phosphorylation level of Ser474, but not that of Thr309, in Akt2 correlates well with insulin-stimulated glucose transport activity in 3T3-L1 adipocytes. 5) The activity of endogenous PTEN may not play a major role in the regulation of glucose transport activity in 3T3-L1 adipocytes.
  • Yasushi Fukushima, Toshihito Saitoh, Motonobu Anai, Takehide Ogihara, Kouichi Inukai, Makoto Funaki, Hideyuki Sakoda, Yukiko Onishi, Hiraku Ono, Midori Fujishiro, Takashi Ishikawa, Kuniaki Takata, Ryozo Nagai, Masao Omata, Tomoichiro Asano
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1539(3) 181-191 2001年6月  
  • M Fujishiro, Y Gotoh, H Katagiri, H Sakoda, T Ogihara, M Anai, Y Onishi, H Ono, M Funaki, K Inukai, Y Fukushima, M Kikuchi, Y Oka, T Asano
    JOURNAL OF BIOLOGICAL CHEMISTRY 276(23) 19800-19806 2001年6月  査読有り
    p38 mitogen-activated protein kinase (MAPK), which is situated downstream of MAPK kinase (MKK) 6 and MKK3, is activated by mitogenic or stress-inducing stimuli, as well as by insulin. To clarify the role of the MKK6/3-p38 MAPK pathway in the regulation of glucose transport, dominant negative p38 MAPK and MKK6 mutants and constitutively active MKK6 and MKK3 mutants were overexpressed in 3T3-L1 adipocytes and L6 myotubes using an adenovirus-mediated transfection procedure. Constitutively active MKK6/3 mutants up-regulated GLUT1 expression and down-regulated GLUT4 expression, thereby significantly increasing basal glucose transport but diminishing transport induced by insulin. Similar effects were elicited by chronic (24 h) exposure to tumor necrosis factor alpha, interleukin-1 beta, or 200 mM sorbitol, all activate the MKK6/3-p38 MAPK pathway. SB203580, a specific p38 MAPK inhibitor, attenuated these effects, further confirming that both MMK6 and MMK3 act via p38 MAPK,whereas they had no effect on the increase in glucose transport induced by a constitutively active MAPK kinase 1 (MEK1) mutant or by myristoylated Akt, In addition, suppression of p38 MAPK activation by overexpression of a dominant negative p38 MAPK or MKK6 mutant did not diminish insulin-induced glucose uptake by 3T3-L1 adipocytes, It is thus apparent that activation of p38 MAPK is not essential for insulin-induced increases in glucose uptake. Rather, p38 MAPK activation leads to a marked down-regulation of insulin-induced glucose uptake via GLUT4, which may underlie cellular stress-induced insulin resistance caused by tumor necrosis factor alpha and other factors.
  • 船木真理, 犬飼浩一, 浅野知一郎, 柴崎芳一, 片桐秀樹, 穴井元暢, 佃克則, 小野啓, 庄嶋伸吾, 木村哲
    日本内分泌学会雑誌 77(1) 169-169 2001年4月  査読有り
  • Takehide Ogihara, Tomoichiro Asano, Katsuyuki Ando, Yuko Chiba, Nobuo Sekine, Hideyuki Sakoda, Motonobu Anai, Yukiko Onishi, Midori Fujishiro, Hiraku Ono, Nobuhiro Shojima, Kouichi Inukai, Yasushi Fukushima, Masatoshi Kikuchi, Toshiro Fujita
    Diabetes 50(3) 573-583 2001年3月1日  
    Previous clinical studies showed an apparent correlation between hypertension and insulin resistance, and patients with diabetes are known to have increased blood pressure responsiveness to salt loading. To investigate the effect of high salt intake on insulin sensitivity and the insulin signaling pathway, a high-salt diet (8% NaCl) or a normal diet was given to 7-week-old SD rats for 2 weeks. High salt–fed rats developed slightly but significantly higher systolic blood pressure than controls (133 ± 2 vs. 117 ± 2 mmHg, P < 0.001), with no change in food intake or body weight. High salt–fed rats were slightly hyperglycemic (108.5 ± 2.8 vs. 97.8 ± 2.5 mg/dl, P = 0.01) and slightly hyperinsulinemic (0.86 ± 0.07 vs. 0.61 ± 0.06 ng/ml, P = 0.026) in the fasting condition, as compared with controls. Hyperinsulinemic-euglycemic clamp study revealed a 52.7% decrease in the glucose infusion rate and a 196% increase in hepatic glucose production in high salt–fed rats, which also showed a 66.4% decrease in 2-deoxyglucose uptake into isolated skeletal muscle and a 44.5% decrease in insulin-induced glycogen synthase activation in liver, as compared with controls. Interestingly, despite the presence of insulin resistance, high salt–fed rats showed enhanced insulin-induced tyrosine phosphorylation of insulin receptor substrate (IRS)-1, IRS-2 (liver and muscle), and IRS-3 (liver only). Phosphatidylinositol (PI) 3-kinase activities associated with IRS and phosphotyrosine in the insulin-stimulated condition increased 2.1- to 4.1-fold, as compared with controls. Insulin-induced phosphorylation of Ser-473 of Akt and Ser-21 of glycogen synthase kinase-3 also increased 2.9- and 2-fold, respectively, in the liver of the high salt–fed rats. Therefore, in both the liver and muscle of high salt–fed rats, intracellular insulin signaling leading to PI 3-kinase activation is enhanced and insulin action is attenuated. The hyperinsulinemic-euglycemic clamp study showed that decreased insulin sensitivity induced with a high-salt diet was not reversed by administration of pioglitazone. The following can be concluded: 1) a high-salt diet may be a factor promoting insulin resistance, 2) the insulin-signaling step impaired by high salt intake is likely to be downstream from PI 3-kinase or Akt activation, and 3) this unique insulin resistance mechanism may contribute to the development of diabetes in patients with hypertension.
  • 迫田秀之, 浅野知一郎, 荻原健英, 大西由希子, 藤城緑, 小野啓, 犬飼浩一, 片桐秀樹, 佃克則, 菊池方利
    糖尿病 44(Suppl.1) S73-S73 2001年3月  査読有り
  • 佃克則, 浅野知一郎, 細川和広, 渥美義仁, 片桐秀樹, 小野啓, 藤城緑, 庄嶋伸浩, 岡芳知, 木村哲
    糖尿病 44(Suppl.1) S51-S51 2001年3月  査読有り
  • Kouichi Inukai, Makoto Funaki, Motonobu Anai, Takehide Ogihara, Hideki Katagiri, Yasushi Fukushima, Hideyuki Sakoda, Yukiko Onishi, Hiraku Ono, Midori Fujishiro, Miho Abe, Yoshitomo Oka, Masatoshi Kikuchi, Tomoichiro Asano
    FEBS Letters 490(1-2) 32-38 2001年2月9日  
    There are five isoforms of the regulatory subunit for the heterodimeric type of phosphatidylinositol 3‐kinase. These five regulatory subunit isoforms were overexpressed using an adenovirus transfection system, and their own tyrosine phosphorylations and associations with various tyrosine kinase receptors were investigated. When overexpressed in CHO‐PDGFR cells, the associations of these regulatory subunit isoforms with the platelet‐derived growth factor receptor were similar. However, when overexpressed in CHO‐IR cells, p55γ exhibited a significantly lower ability to bind with IRS‐1 upon insulin stimulation, as compared with other regulatory subunit isoforms. Furthermore, p55α and p55γ were found to be tyrosine‐phosphorylated. Finally, interestingly, when overexpressed in CHO‐EGFR cells or A431 cells and stimulated with epidermal growth factor (EGF), phosphorylated EGF receptor was detected in p85α, p85β and p50α immunoprecipitates, but not in p55α and p55γ immunoprecipitates. In addition, EGF‐induced tyrosine phosphorylation was observed in p85α, p85β, p55α and p55γ, but not in p50α, immunoprecipitates. Thus, each regulatory subunit exhibits specific responses regarding both the association with tyrosine‐phosphorylated substrates and its own tyrosine phosphorylation. These results suggest that each isoform possesses specific roles in signal transduction, based on its individual tyrosine kinase receptor.
  • Makoto Funaki, Hideki Katagiri, Akira Kanda, Motonobu Anai, Masao Nawano, Takehide Ogihara, Kouichi Inukai, Yasushi Fukushima, Hiraku Ono, Yoshio Yazaki, Masatoshi Kikuchi, Yoshitomo Oka, Tomoichiro Asano
    Journal of Biological Chemistry 274(31) 22019-22024 1999年7月30日  
    Activation of p85/p110-type phosphatidylinositol (PI) kinase has been implicated in various cellular activities. This PI kinase phosphorylates the D-4 position with a similar or higher efficiency than the D-3 position when trichloroacetic acid-treated cell membrane is used as a substrate, although it phosphorylates almost exclusively the D-3 position of the inositol ring in phosphoinositides when purified PI is used as a substrate. Furthermore, the lipid kinase activities of p110 for both the D-3 and D-4 positions were completely abolished by introducing kinase-dead point mutations in their lipid kinase domains (ΔKinα and δKinβ, respectively). In addition, both PI 3- and PI 4-kinase activities of pl10α and pl101β immunoprecipitates were similarly inhibited by either wortmannin or LY294002, specific inhibitors of pl10. Insulin induced phosphorylation of not only the D-3 position, but also the D-4 position. Indeed, overexpression of pl10 in Sf9 or 3T3-L1 cells induced marked phosphorylation of the D-4 position to a level comparable to or much greater than that of D-3, whereas inhibition of endogenous p85/pl10-type PI kinase via overexpression of dominant-negative p85α (Δp85α) in 3T3-L1 adipocytes abolished insulin-induced synthesis of both. Thus, p85/pl10-type PI kinase phosphorylates the D-4 position of phosphoinositides more efficiently than the D-3 position in vivo, and each of the D-3- or D-4-phosphorylated phosphoinositides may transmit signals downstream.
  • 小野 啓, 浅野 知一郎, 後藤 典子, 渋谷 正史, 犬飼 浩一, 船木 真理, 荻原 健英, 大西 由希子, 迫田 秀之, 藤城 緑
    糖尿病 42(Suppl.1) S304-S304 1999年4月  
  • Hideyuki Sakoda, Takehide Ogihara, Motonobu Anai, Makoto Funaki, Kouichi Inukai, Hideki Katagiri, Yasushi Fukushima, Yukiko Onishi, Hiraku Ono, Yoshio Yazaki, Masatoshi Kikuchi, Yoshitomo Oka, Tomoichiro Asano
    Diabetes 48(7) 1365-1371 1999年  
    Membrane glycoprotein plasma cell 1 (PC-1) has been shown to be increased in type 2 diabetes and involved in insulin resistance through inhibiting the insulin receptor tyrosine kinase, which was demonstrated using cultured breast cancer cells. However, other reports have shown contradictory results in Chinese hamster ovary cells and in vitro kinase assay. Thus, we considered it necessary to investigate the effect of PC-1 using highly insulin-sensitive cells. Here, we used two of the following approaches: 1) investigating PC-1 expression levels in insulin-responsive tissues in rat models of diabetes and 2) overexpressing PC-1 in 3T3-L1 adipocytes. We found that PC-1 was highly expressed in insulin-responsive tissues, such as liver and adipose tissue, in normal rats. However, high-fat feeding or streptozotocin-induced diabetes did not change its expression levels in liver, adipose tissue, and skeletal muscle. Thus, PC-1 expression levels were not associated with high-fat-diet-induced insulin resistance or hyperglycemia. Although PC-1 was increased in adipose tissue in Zucker fatty rats (protein level, by 50% mRNA level, by 90%), its expression levels in liver and skeletal muscle, tissues that are more responsible for whole body glucose metabolism than adipose tissue, did not significantly differ from those in normal rats. Next, we overexpressed PC-1 in 3T3-L1 adipocytes using an adenovirus transfection system. PC-1 expression was markedly increased to a level 16-fold greater than that in normal human adipose tissue, which is higher than the previously reported levels in diabetic patients. However, insulin-induced tyrosine phosphorylation of the insulin receptor and insulin receptor substrate 1, activation of phosphatidylinositol 3-kinase, and glucose uptake were not affected by PC-1 overexpression. These results strongly suggest that increased PC-1 expression is not causally related to insulin resistance.
  • 荻原 健英, 浅野 知一郎, 小野 啓, 大西 由希子, 迫田 秀之, 船木 真理, 穴井 元暢, 犬飼 浩一, 石原 寿光, 片桐 秀樹
    糖尿病 41(11) 1047-1047 1998年11月  

MISC

 89

書籍等出版物

 1

講演・口頭発表等

 30

共同研究・競争的資金等の研究課題

 9